Extracellular Phospholipase A&lt;sub&gt;2&lt;/sub&gt; and Histamine Release from Rat Peritoneal Mast Cells

Nagai, Hiroichi; Sakamoto, Tatsuo; Kondo, Masaki; Miura, Tetsuji; Inagaki, Nobuya; Koda, Akihide

doi:10.1159/000235514

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preincubation of pancreatic PLA 2 with AF‐1blocks its activity on mast‐cell degranulation. 65 AFs interact with lipid‐water interfaces 66 and inhibit the increase in fluorescence of Trp 3 in porcine pancreatic sPLA 2 that is normally triggered by binding to micellar substrates. 25 All in all, the most likely explanation for these observations is that, like UG, AFs also inhibit either the interfacial activation or the interaction of sPLA 2 's with lipid‐water interfaces.…”

Section: Mechanism Of Action Of Afsmentioning

confidence: 99%

Antiflammins: Bioactive Peptides Derived from Uteroglobin

Miele

2000

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Uteroglobin/Clara cell 10‐kDa protein (UG/CC10) is a hormonally regulated small secretory protein that has a variety of in vitro and in vivo pharmacological effects. These include a potent anti‐inflammatory activity and inhibitory effects on neutrophil migration, thrombin‐induced platelet aggregation, in vitro chemoinvasion, as well as “tumor suppressor”‐like effects and other properties. Several mechanisms of action have been proposed for these effects. Pharmacological properties suggest that UG itself or substances derived from it may be used as experimental drugs for several indications. The group of oligopeptides collectively known as “antiflammins” (AFs) were originally described in 1988. Their design was derived from the region of highest sequence similarity between UG and another group of proteins with anti‐ inflammatory properties, the lipocortins or annexins. Nanomolar concentrations of these peptides can reproduce several of the pharmacological activities of UG, including its in vivo anti‐inflammatory effects and inhibition of platelet aggregation. The AFs have been safely and effectively used to suppress inflammation and fibrosis in several animal models. Progress in clarifying the mechanism of action of the AFs may facilitate the structure‐based design of a novel class of potent anti‐inflammatory, antichemotactic drugs.

show abstract

Section: Mechanism Of Action Of Afsmentioning

confidence: 99%